Please assess the completion status of the following clinical trial:

Trial Title: Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>/=18 to \</= 80 years of age.~2. Unresected and pathologically (histologic) proven Stage 3a or Stage 3b NSCLC of adenocarcinoma, squamous cell, large cell or mixed histology, diagnosed within three months of study randomization.~3. Non-metastatic disease staged by: CT-chest and upper abdomen, brain MRI or contrast-enhanced CT within 12 weeks and physical examination and whole body FDG-PET/CT scan within 8 weeks prior to study randomization.~Exclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status \>2.~2. More than 10% weight loss in the past 3 months.~3. Diabetic patient or anyone currently taking Metformin, insulin or other anti-hyperglycemic therapy.~4. Pulmonary Function Test (PFTs) (within the last 12 weeks) with Forced Expiratory Volume (FEV)1 \< 1.2 litres per second or less than 50% of predicted.~5. Complete Blood Count (CBC) and biochemical renal and liver function profiles that do not permit chemotherapy treatment (as per institutional standard of care).~6. Fasting blood sugar levels of \>/= 7.0 mmol per litre (within the last 12 weeks).~7. Prior systemic chemotherapy for lung cancer.~8. Prior radiotherapy that would overlap with the planned treatment area.~9. Prior invasive malignancy within the past 3 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity or cervix).~10. Known Acquired Immune Deficiency Syndrome (AIDS).~11. Patients with increased risk for lactic acidosis:~    * severe congestive heart failure (NYHA: class III or IV),~   * history of metabolic acidosis,~   * alcoholic intake of \> 3 drinks daily,~   * severe liver disease,~   * renal failure~12. Known hypersensitivity or allergy to Metformin.~13. Known pregnancy or lactating female patient.~14. Geographic inaccessibility for follow-up.~15. Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metformin plus Chemo-radiotherapy (Type: EXPERIMENTAL): Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
- Chemo-radiotherapy (Type: ACTIVE_COMPARATOR): Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).